Neurodegenerative Diseases

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Alchemab's chief executive, Jane Osbourn

Lilly forges a $415m ALS alliance with UK biotech Alchemab

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.

News

PTC's Huntington study was positive. Why did its stock fall?

In a potentially pivotal trial, PTC Therapeutics' therapy for Huntington's disease met its primary endpoint, but there are questions about the data.

News

Denali's ALS programme suffers another setback

Prospects for Denali Therapeutics' experimental medicine for amyotrophic lateral sclerosis have taken another tumble.

News

SMA treatment with Evrysdi 'could start prenatally'

Should treatment of neurodegenerative disorder SMA with Roche's Evrysdi start even before birth? One case study suggests so.

News

US/EU regulators start review of Biogen's high-dose Spinraza

Biogen's new high-dose version of SMA drug Spinraza has started regulatory reviews - but can it help return the drug to growth?

NRG raises £50m to start trials of Parkinson's, ALS drug

Lilly forges a $415m ALS alliance with UK biotech Alchemab

PTC's Huntington study was positive. Why did its stock fall?

Denali's ALS programme suffers another setback

SMA treatment with Evrysdi 'could start prenatally'

US/EU regulators start review of Biogen's high-dose Spinraza

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Neurodegenerative Diseases

Editor's Picks